[Thromboembolic diseases. XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, 6-12 July 2001].
Lambert
M
M
Service de médecine interne, hôpital Claude-Huriez, CHU, 59037 Lille, France.
D020016:Activated Protein C Resistance; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000175:diagnosis / Q000276:immunology; D001779:Blood Coagulation Factors / Q000032:analysis / Q000235:genetics; D002986:Clinical Trials as Topic; D015331:Cohort Studies; D005165:Factor V / Q000235:genetics; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications; D008297:Male; D009154:Mutation; D016017:Odds Ratio; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy / Q000517:prevention & control; D011379:Prognosis; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000517:prevention & control; D012008:Recurrence; D012307:Risk Factors; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control; D015912:Thrombolytic Therapy; D019851:Thrombophilia / Q000150:complications; D013927:Thrombosis / Q000188:drug therapy / Q000517:prevention & control; D013997:Time Factors; D020246:Venous Thrombosis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology
D000924:Anticholesteremic Agents; D000925:Anticoagulants; D001779:Blood Coagulation Factors; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; C095381:factor V Leiden; D005165:Factor V
Maladies thromboemboliques. XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, 6-12 juillet 2001.